This pipeline uses various statistical tests to identify miRs whose log2 expression levels correlated to selected clinical features.
Testing the association between 509 miRs and 4 clinical features across 155 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 3 clinical features related to at least one miRs.
-
9 miRs correlated to 'Time to Death'.
-
HSA-MIR-361 , HSA-MIR-17 , HSA-MIR-301B , HSA-MIR-130B , HSA-MIR-92A-2 , ...
-
2 miRs correlated to 'AGE'.
-
HSA-MIR-589 , HSA-MIR-21
-
2 miRs correlated to 'GENDER'.
-
HSA-MIR-106A , HSA-MIR-205
-
No miRs correlated to 'RACE'
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=9 | shorter survival | N=9 | longer survival | N=0 |
AGE | Spearman correlation test | N=2 | older | N=2 | younger | N=0 |
GENDER | Wilcoxon test | N=2 | male | N=2 | female | N=0 |
RACE | Kruskal-Wallis test | N=0 |
Time to Death | Duration (Months) | 0.1-175 (median=18.4) |
censored | N = 102 | |
death | N = 52 | |
Significant markers | N = 9 | |
associated with shorter survival | 9 | |
associated with longer survival | 0 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
HSA-MIR-361 | 1.89 | 2.881e-05 | 0.015 | 0.695 |
HSA-MIR-17 | 1.63 | 0.000136 | 0.069 | 0.647 |
HSA-MIR-301B | 1.33 | 0.0001949 | 0.099 | 0.651 |
HSA-MIR-130B | 1.4 | 0.0002653 | 0.13 | 0.653 |
HSA-MIR-92A-2 | 1.65 | 0.0002968 | 0.15 | 0.666 |
HSA-MIR-520B | 1.38 | 0.0002983 | 0.15 | 0.758 |
HSA-MIR-1301 | 1.51 | 0.0003139 | 0.16 | 0.695 |
HSA-MIR-942 | 1.56 | 0.0003269 | 0.16 | 0.663 |
HSA-MIR-421 | 1.51 | 0.0005531 | 0.28 | 0.678 |
AGE | Mean (SD) | 61.45 (13) |
Significant markers | N = 2 | |
pos. correlated | 2 | |
neg. correlated | 0 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-589 | 0.3169 | 5.879e-05 | 0.0299 |
HSA-MIR-21 | 0.2833 | 0.0003538 | 0.18 |
GENDER | Labels | N |
FEMALE | 87 | |
MALE | 68 | |
Significant markers | N = 2 | |
Higher in MALE | 2 | |
Higher in FEMALE | 0 |
W(pos if higher in 'MALE') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-106A | 1870 | 8.803e-05 | 0.0448 | 0.6839 |
HSA-MIR-205 | 520 | 0.0001136 | 0.0577 | 0.7386 |
-
Expresson data file = SARC-TP.miRseq_RPKM_log2.txt
-
Clinical data file = SARC-TP.merged_data.txt
-
Number of patients = 155
-
Number of miRs = 509
-
Number of clinical features = 4
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.